Trial · NCT07901491
SUVY VerSus SAccharose (SUVISA)
NCT07901491, Not applicable, Not yet recruiting, Minerais SAS
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SUVY VerSus SAccharose (SUVISA). Trials, record NCT07901491. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07901491
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SUVY VerSus SAccharose (SUVISA)
- NCT number
- NCT07901491
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 14 participants, estimated
- Lead sponsor
- Minerais SAS
- Conditions
- Healthy Volunteers, Erythritol
- Interventions
- SÜVY, Sucrose
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incremental Area Under the Curve (iAUC) for Blood Glucose and Insulin | 0 to 120 minutes after oral ingestion | Incremental area under the curve (iAUC) for blood glucose and insulin concentrations measured from T0 to T+120 minutes after oral ingestion of SÜVY or sucrose, calculated by the trapezoidal method. Blood samples collected at T0, T+15, T+30, T+45, T+60, T+90 and T+120 minutes. |
| Secondary | Peak Plasma Concentration (Cmax) of Erythritol | 0 to 120 minutes after oral ingestion | Maximum observed plasma concentration of erythritol measured by LC-MS/MS after oral ingestion of SÜVY. |
| Secondary | Time to Peak Plasma Concentration (Tmax) of Erythritol | 0 to 120 minutes after oral ingestion | Time to reach maximum plasma concentration of erythritol measured by LC-MS/MS after oral ingestion of SÜVY. |
| Secondary | Area Under the Plasma Concentration-Time Curve (AUC) of Erythritol | 0 to 120 minutes after oral ingestion | Area under the plasma concentration-time curve of erythritol from time 0 to 120 minutes, calculated by the trapezoidal method, measured by LC-MS/MS. |
| Secondary | Urinary Excretion of Erythritol | 0 to 240 minutes after oral ingestion | Total urinary excretion of erythritol measured by LC-MS/MS in urine collected after oral ingestion of SÜVY. |
| Secondary | Platelet Aggregation (Light Transmission Aggregometry) | At baseline (T0) and T+60 minutes | Platelet aggregation measured by light transmission aggregometry (LTA) using ADP, TRAP-6, collagen and arachidonic acid as agonists. |
| Secondary | Thrombin Generation Assay (TGA/ETP) | At baseline (T0) and T+60 minutes | Endogenous thrombin potential (ETP), peak thrombin and lag time measured by calibrated automated thrombography (CAT). |
| Secondary | Coagulation and Endothelial Markers | At baseline (T0) and T+60 minutes | D-dimers, fibrin monomers, prothrombin time (PT), activated partial thromboplastin time (aPTT), von Willebrand factor antigen (vWF:Ag) and fibrinogen. |
| Secondary | Inflammatory and Endothelial Biomarkers (Luminex Panel) | At baseline (T0) and T+60 minutes | 20-analyte Luminex multiplex panel including inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, IL-8, IL-10, MCP-1), endothelial markers (Ang-1, Ang-2, E-selectin, syndecan-1, thrombomodulin, VEGF) and platelet markers (soluble P-selectin, CXCL4/PF4). |
| Secondary | Digestive Tolerance | At T+60, T+120 and T+240 minutes | Digestive tolerance assessed by visual analogue scale (VAS, 0-10) for bloating, flatulence, abdominal pain and nausea. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07901491
GET https://conductscience.org/api/trials/v1/NCT07901491/registered